255
Coenye T Falsen E, Hoste B, et al. Description of Pandoraeagen. nov. with Pandoraea apista sp. nov., Pandoraea pulmonicola sp. nov., Pandoraea pnomenusa sp. nov., Pandoraea sputorum sp. nov. and Pandoraea norimbergensiscomb. nov. Int J Syst Evol Microbiol 2000; 50(Pt 2): 887-99.
256
Atkinson RM, LipumaJJ, Rosenbluth DB, et al. Chronic colonization with Pandoraea apista in cystic fibrosis patients determined by repetitive-element-sequence PCR. J Clin Microbiol 2006; 44: 833-6.
257
Costello A, Herbert G, Fabunmi L, et al. Virulence of an emerging respiratory pathogen, genus Pandoraea, in vivo and its interactions with lung epithelial cells. J Med Microbiol 2011; 60(Pt 3): 289-99.
258
Jorgensen IM, Johansen HK, Frederiksen B, et al. Epidemic spread of Pandoraea apista,a new pathogen causing severe lung disease in cystic fibrosis patients. Pediatr Pulmonol 2003; 36: 439-16.
259
Coenye T, Goris J, Spilker T, et al. Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis patients and description of Inquilinus limosusgen. nov, sp. nov, J Clin Microbiol 2002; 40: 2062-9.
260
Bittar F, Richet H, Dubus JC, et al. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS One 2008; 3:e2908.
261
Bittar F, Richet H, Dubus JC, et al. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS One 2008; 3:e2908.
262
Bittar F, Leydier A, Bosdure E, et al. Inquilinus limosus and cystic fibrosis. Emerg Infect Dis 2008; 14:993-5.
263
Bittar F, Richet H, Dubus JC, et al. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS One 2008; 3:e2908.
264
Høiby N., Ciofu O, Johansen HK, et al. The clinical impact of bacterial bio-films, Int J Oral Sci 2011; 3: 55–65.
265
Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002;109:317-25.
266
Su S, Hassett DJ. Anaerobic Pseudomonas aeruginosa and other obligated anaerobic bacterial biofilms growing in the thick airway mucus of chronically infected cystic fibrosis patients: an emerging paradigm or "Old Hat"? Expert Opin Ther Targets 2012; 16:859-73.
267
Giliigan PH. Infections in patients with cystic fibrosis: diagnostic microbiology update. Clin Lab Med 2014; 34: 197–217.
268
Zemanick ET, Harris JK, Wagner BD, et al. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. PLoSOne2013;8:e62917
269
Zemanick ET, Harris JK, Wagner BD, et al. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. PLoSOne2013;8:e62917
270
Jones AM. Anaerobic bacteria in cystic fibrosis: pathogens or harmless commensals? Thorax 2011;66:558-9.
271
Zemanick ET, Sagel SD, Harris JK. The airway microbiome in cystic fibrosis and implications for treatment. Curr Opin Pediatr 2011;23:319-24.
272
Smith AL, Fiel SB, Mayer-Hamblett N, et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003; 123: 1495-502.
273
Bryant JM,Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013; 381: 1551-60.
274
Esther CR Jr, Esserman DA, Gilligan R et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9: 117-23.
275
Seddon R Fidler K, Raman S, et al. Prevalence of nontuberculous mycobacteria in cystic fibrosis clinics, United Kingdom, 2009. Emerg Infect Dis 2013; 19: 1128-30.
276
Roux A-L, Catherinot E, Ripoll F, et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J Clin Microbiol 2009; 47: 4124-8.
277
Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/ IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367–416.
278
Esther CR Jr, Esserman DA, Gilligan R et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9: 117-23.
279
Esther CR Jr, Esserman DA, Gilligan R et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9: 117-23.
280
Esther CR Jr, Esserman DA, Gilligan R et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9: 117-23.
281
Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/ IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367–416.
282
Catherinot E, Roux A-L, Vibet M-A, et al. Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients. Eur Respir J 2013; 41: 1101-6.
283
Mussaffi H, Rivlin J, Shalit I, et al. Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J 2005; 25: 324-8.
284
Renna M, Schaffner C, Brown K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011; 121:3554-63.
285
Catherinot E, Roux A-L, Vibet M-A, et al. Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients. Eur Respir J 2013; 41: 1101-6.
286
Binder